Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15415231 | 0.89 | L3MBTL1 (0.47) | MAPTSMN1; SMN2TP53KMT2ANPC1 | |
| SCHEMBL15415214 | 0.80 | OPRK1 (0.38) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL15414949 | 0.76 | CHRM3 (0.36) | MAPTSMN1; SMN2L3MBTL1KDM4ECYP3A4 | |
| SCHEMBL15416134 | 0.73 | MAPT (0.41) | MAPTSMN1; SMN2TP53KMT2ANPC1 | |
| SCHEMBL15415190 | 0.66 | CHRM3 (0.40) | SMN1; SMN2LMNAKDM4EHSD17B10CYP1A2 | |
| SCHEMBL8523468 | 0.66 | SMN1; SMN2 (0.66) | MAPTSMN1; SMN2TP53KMT2ANPC1 | |
| SCHEMBL15415100 | 0.66 | KMT2A (0.56) | MAPTSMN1; SMN2TP53KMT2ANPC1 | |
| SCHEMBL15415808 | 0.65 | ALDH1A1 (0.38) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL11492059 | 0.64 | SMN1; SMN2 (0.67) | MAPTSMN1; SMN2TP53KMT2ANPC1 | |
| SCHEMBL1826048 | 0.64 | SMN1; SMN2 (0.67) | MAPTSMN1; SMN2TP53KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080127-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3080128-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3080123-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-17 | — | — | EP | disclosed |
| EP-3080130-B1 | TRIAZOLOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3080112-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3080129-B1 | IMIDAZOTRIAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3303337-B1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-05-27 | — | — | EP | disclosed |
| EP-3080111-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-05-27 | — | — | EP | disclosed |
| EP-3080118-B1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-03-04 | — | — | EP | disclosed |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2019-11-12 | — | — | US | disclosed |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | EVOTEC (UK) LTD. (GB) | 2016-10-13 | — | — | US | disclosed |
| US-20160297818-A1 | Purine Derivatives As Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-13 | — | — | US | disclosed |
| US-20160297799-A1 | Benzotriazole Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-13 | — | — | US | disclosed |
| US-20160289228-A1 | Tetrahydroimidazopyridine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-06 | — | — | US | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| WO-2015086523-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086506-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | MAPT 1715/4885SMN1; SMN2 411/4885TP53 1808/4885 |
| US-20160297818-A1 | Purine Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, PNP | MAPT 2200/4885SMN1; SMN2 494/4885TP53 2091/4885 |
| US-20160289228-A1 | Tetrahydroimidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | MAPT 873/4885SMN1; SMN2 278/4885TP53 1105/4885 |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | MAPT 913/4885SMN1; SMN2 1329/4885TP53 483/4885 |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | TNF, TNFRSF1A, TNFRSF9 | MAPT 1718/4885SMN1; SMN2 1346/4885TP53 397/4885 |
| US-20160297799-A1 | Benzotriazole Derivatives as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | MAPT 258/4885SMN1; SMN2 1030/4885TP53 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.